"정부 R&D는 20% 불과...이젠 민간 못하는 역할 고민할 때" 2020.12.29 | 동아사이언스 * 기사 제목을 클릭하시면 기사 원문으로 이동합니다.

염한웅 부의장 "바이러스기초연 필요..감염병 R&D 책임부처 둬야" 2020.12.29 | 전자신문  * 기사 제목을 클릭하시면 기사 원문으로 이동합니다.  

□ 국가과학기술자문회의는 ‘국가과학기술자문회의 제13회 심의회의’(이하 심의회의)를 서면으로 개최하여 「제2차 식품·의약품 등의 안전기술 진흥 기본계획(‘21∼‘25)(안)」1개 안건이 심의‧의결되었음을 12월 22일(화) 공표하였다.   ※ 심의회의는 「국가과학기술자문회의법」에 근거한 과학기술 정책 최고 심의기구로서, 의장(대통령), 부의장(염한웅 포스텍 교수) 및 5개 부처 장관, 과학기술보좌관(간사위원), 민간위원 10명 등 총 18명으로 구성   □ 염한웅 부의장은 “국민, 정부 모두가 코로나와 경제위기 극복을 위해 노력하고 있는 가운데, 우리 정부가 포스트코로나 시대에 요구되는 식품․의약품 등의 안전기술을 진흥하기 위해 중장기계획을 수립한 것은 큰 의미가 있다.”라고 언급하면서,   ㅇ “이제 안전하고 건강한 삶을 누리고 싶어 하는 국민의 요구가 더 강해지고 있는 만큼, 오늘 의결된 식품․의약품 등의 안전기술 진흥계획을 통해 정부가 국민 생활 속 안전망을 강화하고, 혁신적인 의료기기 및 의약품이 개발되는 토대를 만들어 나가도록 최선을 다해 달라.”라고 당부하였다.   □ 이번에 상정된 안건의 주요 내용은 다음과 같다. (안건) 제2차 식품·의약품 등의 안전기술 진흥 기본계획(‘21∼‘25)(안)   □ 심의회의는 ｢식품·의약품 등의 안전기술 진흥법｣ 제5조에 따라 수립된 ｢제2차 식품·의약품 등의 안전기술 기본계획(’21~’25)(안)｣을 심의·의결하였다.   □ 이번 계획은 바이오, 인공지능 등 기술 발전을 반영하고 코로나로 촉발된 디지털시대에 필요한 식의약품 등의 안전기술*을 개발하여 국민의 안전하고 건강한 삶을 지원하기 위해 마련되었다. * 식품·의약품 등의 기준·규격설정, 안전성·유효성 평가, 위해 평가, 시험·분석에 관한 기술 및 생산부터 소비까지 全 단계에서의 위해예방·위해요인저감화에 관한 기술   ㅇ 특히 그간 1차 기본계획 추진을 통해 확보된 식의약품 등에 대한 국민 안심수준을 더욱 높이고 ‘25년 식의약 안전기술 수준을 기술 최고국 대비 90%까지 발전시킨다는 목표로 아래 4대 전략을 향후 5년간 추진한다.   □ 우선, 비대면, 무인화 등 뉴노멀시대에 대비하여 식품·의약품 등의 생산·유통·소비 단계별 안전기술을 고도화한다.   ㅇ 식품 생산·수입량, 안전사고 이력 등 빅데이터를 기반으로 식품 위해도 예측 모형을 마련하고 콜드체인, 병원·약국 등에서 수집된 실사용 데이터/증거를 활용한 의료제품 평가기술을 개발하여 스마트 안전관리 기반을 구축하며,   ㅇ 컴퓨터 예측 모델 등 동물을 사용하지 않는 새로운 안전성평가기술을 개발하고 기후변화·환경오염으로 발생하는 해양생물독소, 미세플라스틱 등 새로운 위해요소에 대한 시험법을 개발한다.   □ 또한, 어린이부터 어르신까지 국민 누구나 안전하고 건강한 삶을 누릴 수 있도록 생활 속 안전망을 강화한다.   ㅇ 소비자 특성을 고려한 맞춤형 안전관리를 위해 어린이·고령친화식품의 품질기준과 간·신장 기능 장애 및 소아 환자 대상의 용량 근거를 제시하고 환자 장기추적조사 방안을 마련하여 사용자가 안심하고 제품을 사용할 수 있는 환경을 조성한다. ㅇ 일상생활에서 자주 접하는 위생용품, 화장품, 의약외품과 신종 담배류 등에 대한 시험법과 안전성 평가기술을 개발하고 새로운 감염병이 일상화 되는 환경에 대응하기 위해 백신, 마스크, 진단기기 등 평가기술 플랫폼을 구축한다.   □ 새로운 소재 식품과 세포·유전자치료제, 인공지능 활용 의료기기 등 혁신제품에 대한 안전기술 개발을 통해 과학 기반의 합리적 규제환경을 조성한다.   ㅇ 이를 위해 새로운 식품원료(유전자변형식품, 세포배양육)와 건강기능식품의 안전성 및 기능성 평가기술과 특수의료용도식품 제조기준 등을 개발하여 제품화를 지원한다.   ㅇ 희귀·난치질환 치료를 위해 세포·유전자치료제 등 첨단바이오의약품의 안전성·유효성 평가기술과 디지털 치료기기(전자약) 등 혁신의료기기의 안전기술을 개발하여 환자 치료기회를 확대한다.   □ 아울러 민관이 함께 개방·공유, 협력하고 전문성을 강화하여 상생 발전하는 규제과학 연구생태계를 구축한다.   ㅇ 민간이 참여하는 개방형 기획 등 연구개발 수행체계를 강화하고 연구데이터 공유플랫폼을 구축하며, 연구성과를 활용한 정확한 정보 제공으로 국민과의 과학적 소통을 강화한다.   ㅇ 식품·의약품 등 안전성·유효성·품질을 평가하는 ‘규제과학’ 연구역량을 강화하기 위해 전문인력을 양성하는 동시에 민·관 R&D 협력체계를 확대한다.   □ 식약처는 이번 기본계획을 통해 식품·의약품 등의 안전기술을 체계적으로 발전시켜, 식품·의약품 등의 안전사용을 위한 과학적·합리적 규제환경을 조성함으로써 국민의 건강하고 행복한 삶을 지원해 나갈 예정이다.  

"2025년까지 식의약품 안전기술 수준 제고..빅데이터 적용"(연합뉴스) 정부, 식의약 안전기술 수준 2025년 기술최고국 90% 달성 추진(뉴시스) 바이오, 비대면 등 안전기술 발전 기본계획 심의‧의결(약업신문) 과학기술자문회의 개최…‘식품ㆍ의약품 안전기술 진흥 계획’ 의결(이투데이) 국가과학기술자문회의 제13회 심의회의 개최(이뉴스투데이) * 기사 제목을 클릭하시면 기사 원문으로 이동합니다.  

염한웅 부의장, "대학이 변해야 하는데..변화 유도 쉽지 않다" 토로 2020.12.21 | 뉴스1 * 기사 제목을 클릭하시면 기사 원문으로 이동합니다.  

[특별인터뷰]염한웅국가 국가과학기술자문회의 부의장 "공공 R&D 비중-역할 대폭 늘려야" 2020.12.09 | 전자신문 * 기사 제목을 클릭하시면 기사 원문으로 이동합니다.  

제1장 서론 ········································································································································1 1. 연구의 필요성 및 목표 ······································································································1 2. 연구의 내용 및 범위 ··········································································································2 3. 연구의 방법 및 추진체계 ··································································································3 제2장 국내외 과학기술 동향 및 이슈 개괄 ··············································································6 제1절. 국내외 과학기술 주요 정책 동향 ················································································6 1. 국내외 과학기술정책 동향 개괄 ······················································································6 2. 해외 주요국 동향 ················································································································8 3. 우리나라 동향 ····················································································································16 제2절. 과학기술 주요 의제에 관한 선행연구 ····································································21 1. 선행연구 조사목록 ············································································································21 2. 혁신시스템·주체별 의제 검토 ······················································································22 3. 이슈·동향 중심 의제 검토 ····························································································26 제3절. 소결 ··································································································································33 제3장 과학기술분야 중장기 이슈의 발굴 ················································································35 제1절. 이슈 발굴의 관점과 절차 ····························································································35 1. 이슈 발굴의 관점 ··············································································································35 2. 이슈 발굴 절차 및 방법 ··································································································36 3. 이슈 발굴 일차 결과 ········································································································47 4. 이슈 발굴 최종 결과 ········································································································52 제4장 과학기술분야 10대 주요 이슈 ························································································53 제1절. 개요 ································································································································53 제2절. 상세 내용 ························································································································54 제5장 과학기술분야 주요 이슈의 의제화 방향 ······································································75 제1절. 주요 이슈 선별 및 심화 과정 ····················································································75 제2절. 4대 주요이슈 ················································································································77 1. 미래인재 양성과 지속가능 과기인력 확충 ································································77 2. 기술이전·사업화 활성화를 위한 산학연 협력 강화 ··············································87 3. 데이터-AI 통합 지원과 디지털 경제·사회로의 전환 ·············································94 4. 감염병 대응 솔루션의 국가자산화 및 신뢰 기반 성장 ······································103 참고문헌 ······································································································································114